Total Pageviews

Monday, November 29, 2021

Summary of Evidence for Ivermectin / Fluvoxamine (Movie What is Ivermectin?)

+++

What is Ivermectin? 
Starts 11 minutes 

+++

 

+++

 Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID19 Pierre Kory, MD et al.  Use the attached link for full article or read summary below.  


FLCCC I-MASK Protocol 11.29.2021 




Abstract 

In March 2020, the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik to continuously review the rapidly emerging basic science, translational, and clinical data to develop a treatment protocol for COVID-19. The FLCCC then recently discovered that ivermectin, an anti-parasitic medicine, has highly potent anti-viral and anti-inflammatory properties against COVID-19. They then identified repeated, consistent, large magnitude improvements in clinical outcomes in multiple, large, randomized and observational controlled trials in both prophylaxis and treatment of COVID-19.

Further, data showing impacts on population wide health outcomes have Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 [FLCCC Alliance; updated Jan 16, 2021] 2 / 30 www.flccc.net resulted from multiple, large “natural experiments” that occurred when various city mayors and regional health ministries within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective.

The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin may prove to be a global solution to the pandemic. This was further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Belize, Macedonia, and the state of Uttar Pradesh in Northern India, populated by 210 million people.

To our knowledge, the current review is the earliest to compile sufficient clinical data to demonstrate the strong signal of therapeutic efficacy as it is based on numerous clinical trials in multiple disease phases. 

One limitation is that half the controlled trials have been published in peer-reviewed publications, with the remainder taken from manuscripts uploaded to medicine pre-print servers. Although it is now standard practice for trials data from pre-print servers to immediately influence therapeutic practices during the pandemic, given the controversial therapeutics adopted as a result of this practice, the FLCCC argues that it is imperative that our major national and international health care agencies devote the necessary resources to more quickly validate these studies and confirm the major, positive epidemiological impacts that have been recorded when ivermectin is widely distributed among populations with a high incidence of COVID-19 infections.


Introduction 

In March 2020, an expert panel called the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik.1 The group of expert critical care physicians and thought leaders immediately began continuously reviewing the rapidly emerging basic science, translational, and clinical data in COVID-19 which then led to the early creation of a treatment protocol for hospitalized patients based on the core therapeutic interventions of methylprednisolone, ascorbic acid, thiamine and heparin (MATH+), with the “+” referring to multiple, optional adjunctive treatments. 

The MATH+ protocol was based on the collective expertise of the group in both the research and treatment of multiple other severe infections causing lung injury. 

Two manuscripts reviewing different aspects of both the scientific rationale and evolving published clinical evidence in support of the MATH+ protocol were published in major medical journals at two different time points in the pandemic (Kory et al., 2020;Marik et al., 2020). 

The most recent paper reported a 6.1% hospital mortality rate in COVID-19 patients measured in the two U.S hospitals that systematically adopted the MATH+ protocol (Kory et al., 2020). This was a markedly decreased mortality rate compared to the 23.0% hospital mortality rate calculated from a review of 45 studies including over 230,000 patients (unpublished data; available on request). 

Although the adoption of MATH+ has been considerable, it largely occurred only after the treatment efficacy of the majority of the protocol components (corticosteroids, ascorbic acid, heparin, statins, Vitamin D, melatonin) were either validated in subsequent randomized controlled trials or more strongly supported with large observational data sets in COVID-19 (Entrenas Castillo et al., 2020;Horby et al., 2020;Jehi et al., 2020;Nadkarni et al., 2020;Rodriguez-Nava et al., 2020;Zhang et al., 2020a;Zhang et al., 2020b). 

Despite the plethora of supportive evidence, the MATH+ protocol for hospitalized patients has not yet become widespread. 

Further, the world is in a worsening crisis with 1 https://www.flccc.net Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 [FLCCC Alliance; updated Jan 16, 2021] 3 / 30 www.flccc.net the potential of again overwhelming hospitals and ICU’s. 

As of December 31st, 2020, the number of deaths attributed to COVID-19 in the United States reached 351,695 with over 7.9 million active cases, the highest number to date. 2 Multiple European countries have now begun to impose new rounds of restrictions and lockdowns.3 Further compounding these alarming developments was a wave of recently published results from therapeutic trials done on medicines thought effective for COVID-19 which found a lack of impact on mortality with use of remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon, convalescent plasma, tocilizumab, and mono-clonal antibody therapy (Agarwal et al., 2020;Consortium, 2020;Hermine et al., 2020;Salvarani et al., 2020). 4 

One year into the pandemic, the only therapy considered “proven” as a life-saving treatment in COVID-19 is the use of corticosteroids in patients with moderate to severe illness (Horby et al., 2020).

Similarly, most concerning is the fact that little has proven effective to prevent disease progression to prevent hospitalization. Fortunately, it now appears that ivermectin, a widely used anti-parasitic medicine with known anti-viral and anti-inflammatory properties is proving a highly potent and multi-phase effective treatment against COVID-19. Although growing numbers of the studies supporting this conclusion have passed through peer review, approximately half of the remaining trials data are from manuscripts uploaded to medical pre-print servers, a now standard practice for both rapid dissemination and adoption of new therapeutics throughout the pandemic.

The FLCCC expert panel, in their prolonged and continued commitment to reviewing the emerging medical evidence base, and considering the impact of the recent surge, has now reached a consensus in recommending that ivermectin for both prophylaxis and treatment of COVID-19 should be systematically and globally adopted. 

The FLCCC recommendation is based on the following set of conclusions derived from the existing data, which will be comprehensively reviewed below: 

1) Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue and others (Mastrangelo et al., 2012;Wagstaff et al., 2012;Tay et al., 2013;Götz et al., 2016;Varghese et al., 2016;Atkinson et al., 2018;Lv et al., 2018;King et al., 2020;Yang et al., 2020).

2) Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue via several observed and proposed mechanisms (Caly et al., 2020a). 

3) Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation (Zhang et al., 2008;Ci et al., 2009;Zhang et al., 2009). 

4) Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses (Arevalo et al., 2020;de Melo et al., 2020).

5) Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients (Behera et al., 2020;Bernigaud et al., 2020;Carvallo et al., 2020b;Elgazzar et al., 2020;Hellwig and Maia, 2020;Shouman, 2020). 


Discussion

It is the authors opinion, that based on the totality of these data, the use of ivermectin as a prophylactic and early treatment option should receive an A-I level recommendation by the NIH in support of use by the nation’s health care providers. When, or if, such a recommendation is issued, the Front Line COVID-19 Critical Care Alliance has developed a prophylaxis and early treatment protocol for COVID-19 (I-MASK+), centered around ivermectin combined with masking, social distancing, hand hygiene, Vitamin D, Vitamin C, quercetin, melatonin, and zinc, with all components known for either their anti-viral, anti-inflammatory, or preventive actions. 

The I-MASK+ protocol suggests treatment approaches for prophylaxis of high-risk patients, post-exposure prophylaxis of household members with COVID-19, and an early treatment approach for patients ill with COVID-19. 

I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 Prophylaxis Protocol MEDICATION RECOMMENDED DOSING lvermectin Prophylaxis for high-risk individuals: SEE  FULL ARTICLE link is above at beginning of this post.  

In summary, based on the existing and cumulative body of evidence, we recommend the use of ivermectin in both prophylaxis and treatment for COVID-19. In the presence of a global COVID-19 surge, the widespread use of this safe, inexpensive, and effective intervention would lead to a drastic reduction in transmission rates and the morbidity and mortality in mild, moderate, and even severe disease phases. The authors are encouraged and hopeful at the prospect of the many favorable public health and societal impacts that would result once adopted for use. 


+++

Fluvoxamine for COVID: what you need to know

I funded the original study, I was featured on 60 Minutes, and have been in touch with the researchers on all the trials that have been done in the US, Brazil, and Croatia.


12. Substitutions. You can use fluoxetine as well (aka Prozac). Dosage there is 30mg once a day. Some countries don’t have fluvoxamine so this is the alternative. Also, for people who can’t tolerate fluvoxamine for whatever reason (nausea, jittery, etc), this is the alternative.

19.Government agencies are ignoring the science. NIH and WHO refuse to acknowledge it works since it will cause vaccine hesitancy if it is known that there is a drug that turns COVID into a mild disease. That’s why they didn’t change their recommendation when the Phase 3 trial was published in Lancet. I fully expected both organizations to do absolutely nothing. They knew in advance it was coming and on the day the paper was published they ignored it entirely.

20. Comparison with molnupiravir. Fluvoxamine is way better than Molnupiravir, but the NIH doesn’t approve drugs on effectiveness. It’s whether Merck can make a killing that matters. Think about it … Molnupiravir has a 50% risk reduction whereas fluvxoamine is over 90%. Fluvoxamine has a 40 year safety track record. Molnupiravir followed patients for only 30 days because they know the drug is dangerous. The NIH picks the drug that makes the most money for the drug companies regardless of long-term safety… Molnupiravir!

No comments:

Post a Comment